Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on May 17, 2021. The filing serves to announce the company's financial results for the three-month period ended March 31, 2021. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in Alameda, California.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the source text. Consequently, no specific financial figures can be extracted from this document alone.
Material Changes
The filing does not provide data to compare current period results against prior comparable periods. The document solely references the issuance of a press release regarding the Q1 2021 results without detailing the specific variances or material changes within the text of the 8-K.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks and uncertainties.
- Risk Factors: Investors are directed to the "Risk Factors" section of AgeX's periodic reports filed with the SEC for additional factors that could cause actual results to differ materially from anticipated results.
- Outlook: No specific guidance or management commentary regarding future performance is provided in the text of this 8-K.
Important Facts for Investor Verification
- Verify the specific financial results (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated May 17, 2021), as the 8-K text does not list these numbers.
- Confirm the company name is AgeX Therapeutics, Inc. (Ticker: AGE), noting the discrepancy in the request metadata which listed "Serina Therapeutics, Inc."
- Review the company's most recent 10-Q or 10-K filings for detailed risk factors and historical financial comparisons not present in this current report.
- Note that the information in Item 2.02 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.